While Cowen analyst Phil Nadeau believes the selloff on Wednesday in shares of Immunomedics (IMMU) is due to concerns related to the Food and Drug Administrationâs Form 483 observations from a recent inspection of the companyâs New Jersey facility, he remains confident the ASCENT trial will succeed and that sacituzumab will become standard of care in triple-negative breast cancer. Also commenting on… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3064952/-Immunomedics-slide-pinned-on-FDA-facility-inspection-report)